|
New Report Measures the Impact of Nanotechnologies Currently Being Applied to Target Cancer, Cardiovascular Disease and CNS Disorders
DUBLIN, Ireland - Februarty 14,2008 - Research and Markets (http://www.researchandmarkets.com/reports/c82834) has announced the addition of Nanotechnology: Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics to their offering.
Nanotechnologies have already attracted
over $3bn of global government funding as part of efforts to enhance
a range of disciplines including pharmaceuticals, drug delivery and
healthcare monitoring. Advances in nanomaterials, nanostructures and
nanosystems are expected to drive the value of the global
nanotechnology market to over a trillion dollars by 2015, but many
companies are remaining cautious, preferring to monitor developments
in academia prior to making substantial investments.
Despite such trepidation, the pharma
industry is beginning to adopt nanotools throughout the R&D process
to facilitate the high throughput screening of drug repositories,
the identification of new drug targets and biomarkers for
preclinical and clinical studies and the development of diagnostics
and imaging agents. ‘Nanotechnology’ is a new report published by
Business Insights that provides a comprehensive review of
nanotechnology and it’s role in the development of next-generation
nanomedicines. The nanotools and detection systems currently driving
nanotechnology are profiled and the applications of nanotechnologies
within the R&D process are assessed.
This report measures the impact of
nanotechnologies currently being applied to target cancer,
cardiovascular disease and CNS disorders and also explores the
implementation strategies of leading pharmaceutical, healthcare and
nanotechnology start-ups. Use this new report to assess the future
of nanotechnology within pharma R&D, identify the innovations
driving growth within the market and examine the implementation
strategies of leading companies.
Key Findings
-Nano-enabled delivery systems are the
fastest growing form of nanotechnology amongst major pharma
companies, helping to improve the targeted delivery of old, existing
and shelved products. However many companies remain cautious,
choosing to monitor the progress of nanotechnology prior to making
significant investments.
- Optical imaging tags will help to
identify diseases earlier and may avoid the need for expensive, high
tech laser-based equipment. Diagnostic imaging of this kind is being
increasingly applied to animals in preclinical dosing studies.
- Regulatory authorities are supporting
nanotechnologies that can improve the development of pharmaceuticals
and diagnostic agents. Many regulatory policies are currently being
reassessed to ensure innovation and safety when utilising
nanotechnologies.
- Many governments are keen to apply
nanotechnology across pharmaceuticals, drug delivery and healthcare
monitoring in an effort to reduce R&D costs and enhance levels of
productivity.
-Nanomaterials are being utilised to
develop more sensitive and specific POC diagnostic and biocompatible
implants. Nanowires and cantilever assay systems will expand the
market by helping to shift diagnostic tests from central
laboratories to point of diagnostics.
Key Questions Answered
-What is the role of nanotechnology in
preclinical and clinical drug development?
- Which new nanotools and nanomaterials
are driving growth?
- How is biomarker harvesting being
affected by nanotechnology?
- Which major companies are developing
nano enabled delivery systems?
- How are new optical tagging agents
aiding animal dosing studies in the clinical development of safety
assessment candidates?
- Which nanotechnologies are driving
innovation in POC diagnostics?
- How are companies incorporating
nanotechnology into their R&D programmes?
Key Issues Examined
-Nanotech acquisitions. The potential
acquisition of nanotech companies and in-licensing technologies is
becoming a popular trend amongst pharma companies who are keen to
counter the effects of industrial consolidation and low
productivity.
- Go/no-go decision-making. The
application of nanotechnology in biomarker discovery has enhanced
the identification and validation of novel biomarkers for use in the
pre-clinical and clinical development process, helping companies to
engage in go/no-go decision-making significantly earlier.
- Fast-evolving technology platform.
Novel nanomaterials are being evaluated as nanostructures whilst
others have potential as biocompatible and biodegradable medical
coatings and
implants. The evolution of nano-enabled
delivery systems may provide targeted delivery solutions for
approved and upcoming agents and also help to reposition shelved
products.
- Disease diagnosis/treatment. New
nanotools that enhance contrast agents and improve optical imaging
are expected to contribute in the earlier stages of disease
diagnosis, and the construction of electrical/thermal nanosensors
and nanodevices will help to diagnose, monitor and treat a disease.
Companies Mentioned:
- AstraZeneca
- Bristol-Myers Squibb
- GlaxoSmithKline
- Novartis
- Roche
- Pfizer
- Elan Corporation
- Genentech
- GE Healthcare
- Siemens Medical Solutions
- Abraxis BioSciences
- pSividia Limited
- StarPharma Holdings Ltd
For more information visit http://www.researchandmarkets.com/reports/c82834
For more information contact:
Research and Markets
Laura Wood, Senior Manager
Fax: +353 1 4100 980
Email : press@researchandmarkets.com
Source: Business Insights
Would you like to see your news and articles here? GO>>
Disclaimer: The views and opinions expressed in the research published are those of the individual companies and writers and not necessarily those of Investorideas.com®, or any of the industry sector portals . At the time of publication, writers may hold positions in the stocks or companies mentioned.
Investorideas.com® or any of the industry sector portals cannot assure accuracy of the research presented. Investors are encouraged to research and verify facts and under no circumstances is Investorideas.com® endorsing the content as a recommendation to buy or sell stock.
|
